Moving toward disease modification in polycythemia vera

Abstract

Polycythemia vera (PV) belongs to the BCR-ABL1-negative myeloproliferative neoplasms and is characterized by activating mutations in JAK2 and clinically presents with erythrocytosis, variable degrees of systemic and vasomotor symptoms, and an increased risk of both thromboembolic events and progression to myelofibrosis and acute myeloid leukemia (AML). Treatment selection is based on a patient's age and a history of thrombosis with low-risk PV patients treated with therapeutic phlebotomy and aspirin alone, while cytoreductive therapy with either hydroxyurea or interferon (IFN)-α is added for high-risk disease. However, other disease features such as significant disease-related symptoms and splenomegaly, concurrent thrombocytosis and leukocytosis, or intolerance of phlebotomy can constitute an indication for cytoreductive therapy in otherwise low-risk patients. Additionally, recent studies demonstrating the safety and efficacy (i.e., reduction in phlebotomy requirements and molecular responses) of ropegylated IFN-α-2b support its use in low-risk PV patients. Additionally, emerging data suggest that early treatment is associated with higher rates of molecular responses, which might eventually enable time-limited therapy. Nonetheless, longer follow-up is needed to assess whether molecular responses associate with clinically meaningful outcome measures such as thrombosis and progression to myelofibrosis or AML. In this review, we provide an overview of the current and evolving treatment landscape of PV and outline our vision for a patient-centered, phlebotomy-free, treatment approach using time-limited, disease-modifying treatment modalities early in the disease course, which could ultimately impact the natural history of the disease.

Extensive Hepatic Infarction due to Polycythemia Vera

“…Polycythemia vera is a BCR-ABL1-negative myeloproliferative neoplasm characterized by activating mutations in JAK2, which clinically presents with erythrocytosis and has an increased risk of both thromboembolic events and progression to myelofibrosis and acute myeloid leukemia [1,2]. Splanchnic vein thrombosis is a rare manifestation of venous thromboembolism in one or more abdominal vessels and is strongly associated with PV [3].…”